Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III ...

Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.

Although external debt inflows continue to rise, government revenue growth has failed to keep pace, pushing key debt indicators closer to risk thresholds ...

Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 2:30 PM ESTCompany ParticipantsRafael Amado - President and Head ...

Hello, and welcome to WalesOnline's live blog for Friday, February 20. We'll be bringing you all of the latest news from ...

Is there a greater testament to artistic endeavour than Florence? The Tuscan city positively brims with museums, galleries ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

Public Works Director Brian Spindor says King County Flood Control needs to complete a flood map before the city can engineer ...